Total Voting Rights

RNS Number : 4800E

Hemogenyx Pharmaceuticals PLC

28 February 2020

 

28 February 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Total Voting Rights

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company consists of 397,253,969 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 397,253,969.

The figure of 397,253,969 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries	Tel: [phone]
Lowell Goodman	[e-mail]

 

END

 

 

TVREAPAPASPEEEA